HTA and payment mechanisms for new drugs to tackle AMR

HTA and payment mechanisms for new drugs to tackle AMR This paper provides an overview of the current state of health technology assessment and contracting for antibiotics in five European countries (France, Germany, Italy, Sweden and the UK), and of the recent proposals in the literature for revising them. It also includes the recommendations developed following a stakeholder forum on ‘Value Assessment and Contracting for Antibiotics’ held in February 2019. Office of Health Economics